- Home
- AMSF vs PHVS Comparison
AMSF vs PHVS Comparison
Compare AMSF & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSF
- PHVS
- Stock Information
- Founded
- AMSF 1985
- PHVS 2015
- Country
- AMSF United States
- PHVS Netherlands
- Employees
- AMSF N/A
- PHVS N/A
- Industry
- AMSF Accident &Health Insurance
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- AMSF Finance
- PHVS Health Care
- Exchange
- AMSF Nasdaq
- PHVS Nasdaq
- Market Cap
- AMSF 930.7M
- PHVS 1.0B
- IPO Year
- AMSF 2005
- PHVS 2021
- Fundamental
- Price
- AMSF $51.04
- PHVS $22.64
- Analyst Decision
- AMSF Buy
- PHVS Buy
- Analyst Count
- AMSF 1
- PHVS 6
- Target Price
- AMSF $65.00
- PHVS $35.67
- AVG Volume (30 Days)
- AMSF 120.6K
- PHVS 74.1K
- Earning Date
- AMSF 10-23-2024
- PHVS 11-04-2024
- Dividend Yield
- AMSF 2.90%
- PHVS N/A
- EPS Growth
- AMSF N/A
- PHVS N/A
- EPS
- AMSF 2.97
- PHVS N/A
- Revenue
- AMSF $309,130,000.00
- PHVS N/A
- Revenue This Year
- AMSF N/A
- PHVS N/A
- Revenue Next Year
- AMSF N/A
- PHVS N/A
- P/E Ratio
- AMSF $17.16
- PHVS N/A
- Revenue Growth
- AMSF 1.25
- PHVS N/A
- 52 Week Low
- AMSF $41.97
- PHVS $15.00
- 52 Week High
- AMSF $54.80
- PHVS $33.00
- Technical
- Relative Strength Index (RSI)
- AMSF 64.16
- PHVS 72.43
- Support Level
- AMSF $47.56
- PHVS $17.28
- Resistance Level
- AMSF $51.56
- PHVS $22.12
- Average True Range (ATR)
- AMSF 0.91
- PHVS 1.09
- MACD
- AMSF 0.29
- PHVS 0.40
- Stochastic Oscillator
- AMSF 85.09
- PHVS 99.81
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance to employers engaged in hazardous industries, mainly construction, trucking, manufacturing, oil and gas, and agriculture. The company generates a majority of its revenue in the form of premiums.
About PHVS Pharvaris N.V.
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. The company's activities are considered to be one segment which comprises the discovery, development and commercialization of oral bradykinin-B2-receptor antagonists .